Seventeen Peptide Guidance Revised: What Developers Need to Know

The FDA released revised draft product-specific guidances on July 28, 2026 for 17 peptide products, covering reference drugs used to treat type 2 diabetes, obesity, osteoporosis, and macular degeneration.¹ The list spans well-known therapies including semaglutide, tirzepatide, liraglutide, teriparatide, and pegcetacoplan, along with older peptide drugs such as calcitonin salmon and glucagon.

Product-specific guidances give generic-drug developers a roadmap for what the agency expects to see in an abbreviated new drug application.¹ They are not binding requirements, but they function as the clearest available signal of how reviewers will evaluate a proposed generic against its brand-name counterpart.

What Changed in This Round of Guidance?

The revisions update the FDA's recommendations across 5 technical areas: how recombinantly, synthetically, or semi-synthetically produced peptides should be submitted, innate immune response testing, impurity thresholds, higher order structure assessment, and biological activity assessment.¹ Together, these categories touch nearly every stage of demonstrating that a generic peptide is therapeutically equivalent to its reference product.

Peptides occupy a difficult middle ground in generic drug science.¹ They are more structurally complex than small-molecule drugs, where identical chemical structure is generally sufficient to establish sameness, but they are typically less complex than large biologic proteins, which require an entirely separate regulatory pathway. That in-between status has long made peptide characterization a point of scientific debate, particularly around how much structural and functional similarity is enough to satisfy regulators without demanding biologic-level comparability studies.

The agency also withdrew its 2021 guidance on synthetic peptide products referencing biologic-origin drugs, stating it no longer reflects current scientific thinking.¹ A replacement is expected later in 2026, according to the agency's most recent guidance agenda.

Why Does This Matter for Manufacturing and Development Teams?

For contract development and manufacturing organizations and generic-drug manufacturers already active in the GLP-1 space, the guidance offers clearer analytical expectations at a moment when semaglutide and tirzepatide generics are drawing intense commercial interest as patents and exclusivity periods near their end.¹ Updated thresholds for impurities and revised expectations for structural and functional testing directly affect how analytical development programs and specification-setting are designed, and gaps between old and new expectations can mean rework for programs already underway.

The changes also matter beyond the diabetes and obesity drugs likely to draw the most attention.¹ Older peptide therapies for osteoporosis and macular degeneration are included as well, suggesting the agency is applying a more consistent scientific framework across its peptide portfolio rather than addressing individual drug classes in isolation.

The FDA frames the update as part of a broader effort to expand access to lower-cost generic alternatives, tying the guidance to both its Drug Competition Action Plan and a 2025 executive order directing agencies to accelerate generic and biosimilar approvals.¹ The agency noted that its recommendations may extend to other generic peptide products not explicitly listed, and it encouraged sponsors developing those products to raise questions through a formal meeting request or controlled correspondence with the Office of Generic Drugs.

The guidance documents remain in draft form, and the FDA will review public comments before finalizing them.¹ For companies with peptide generics in active development, the comment period represents a practical opportunity to flag where proposed testing requirements may be difficult to execute or where clarification is needed before the recommendations take effect.

How Can Stakeholders Weigh In Before the Guidance Is Finalized?

The Federal Register notice accompanying the draft guidance sets a comment deadline of September 28, 2026, giving developers roughly two months to flag concerns before FDA begins work on final versions.² Comments can be submitted electronically through the federal government's rulemaking portal or as written submissions to the agency's Dockets Management Staff.

Notably, the guidance documents remain non-binding even once finalized.² Sponsors may pursue alternative approaches to bioequivalence study design if those approaches still satisfy applicable statutes and regulations, though doing so typically invites closer regulatory scrutiny than following the published recommendations directly. Companies with confidential or proprietary manufacturing details relevant to their comments have the option to submit written filings marked accordingly, keeping sensitive process information out of the public docket while still ensuring it factors into the agency's review.

What Standard Are Generic Peptide Products Ultimately Held To?

Underlying every product-specific guidance is a consistent regulatory bar: pharmaceutical equivalence, bioequivalence, and therapeutic equivalence to the reference product.² A generic must match the reference drug's active ingredient, dosage form, strength, and route of administration, then demonstrate no significant difference in absorption rate and extent.

These expectations trace back to the agency's user fee commitments, which set target timelines for issuing guidance after a reference product's approval, with complex products like peptides given longer development windows than simpler drugs.² That framework helps explain why guidance for these products is only now catching up to years of accumulated peptide characterization science.

References

1. FDA publishes revised draft product-specific guidances for certain generic peptide products. FDA. July 28, 2026. Accessed July 29, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-publishes-revised-draft-product-specific-guidances-certain-generic-peptide-products
2. FDA. Product-specific guidances; revised draft guidances for industry; availability. Federal Register. 2026 Jul 29;91(144):47834-47835. Available from: https://www.govinfo.gov/content/pkg/FR-2026-07-29/pdf/2026-15285.pdf